Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT05744713

An Observational Study of Patients With Chronic Liver Disease

TARGET-Liver Disease (TARGET-LD) is an observational research study to conduct a comprehensive review of outcomes for patients with chronic liver disease (CLD).

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Chronic Liver Disease Cirrhosis Fibrosis Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Keck School of Medicine of USC, Los Angeles, California, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Disease Cohort

•Adult* patients at the time of enrollment with a diagnosis of CLD/cirrhosis by ICD-10 code in the EHR interface

Engaged Cohort

  • Adult* patients diagnosed and managed for CLD/cirrhosis invited to participate
  • Ability to provide written informed consent

Exclusion criteria

Disease Cohort

  • Death
  • Manual removal (sponsor or site request)
  • No EHR interface encounter > 3 years.

Engaged Cohort

  • Patient expressed desire to withdraw consent to complete PROs
  • Failure to complete PROs within 24 weeks of initial invitation
  • Greater than 24 months lapse of survey completion after baseline surveys completed
  • Additionally, the criteria detailed for Disease Cohort apply to the Engaged Cohort.

Treatment and study plan

Observational

Other

Observational

Primary outcomes

  1. To characterize the natural history of disease in patients with CLD from various etiologies and Cirrhosis

    Time frame: 20 Years

  2. To assess safety and effectiveness of CLD/Cirrhosis treatments and treatments for complications of any chronic liver disease

    Time frame: 20 Years

  3. To establish learning health networks focused on quality of care for patients

    Time frame: 20 Years

Secondary outcomes

  1. To evaluate provider management practices in the treatment of patients with CLD/Cirrhosis

    Time frame: 20 Years

  2. To evaluate longitudinal and patient reported outcomes in CLD/Cirrhosis

    Time frame: 20 Years

Sponsors and collaborators

Lead sponsor

Target PharmaSolutions, Inc.

Industry

Registry information

Important dates

Study start
2024
Primary completion
2037
Study completion
2037
First posted
Feb 27, 2023
Registry last updated
Mar 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.